BRAF and neoplasm: Although the molecular mechanism underlying this observation remain to be elucidated, it clearly suggests that the new molecule MR30 could be a potent agent for the therapy of tumours in which the above genes (i.e. PTEN, K-RAS, B-RAF) are biomarkers for resistance to gefitinib.